{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:43:37Z","timestamp":1792601017998,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ophtha.2026.04.008","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:58:09Z","timestamp":1778770689000},"page":"1029-1035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy"],"prefix":"10.1016","volume":"133","author":[{"given":"Sarah W.","family":"DeParis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isdin","family":"Oke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Gaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"MacIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrey L.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"Dinkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2026.04.008_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2026.04.008_bib3","unstructured":"GLP-1 injectable use among adults with diagnosed diabetes: United States, 2024. Centers for Disease Control and Prevention. Accessed November 26, 2025. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db537.htm."},{"key":"10.1016\/j.ophtha.2026.04.008_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/WNO.0000000000002102","article-title":"Reexamining the incidence of nonarteritic anterior ischemic optic neuropathy: a Rochester Epidemiology Project study","volume":"44","author":"Foster","year":"2024","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0002-9394(14)70999-7","article-title":"Incidence of nonarteritic anterior ischemic optic neuropathy","volume":"123","author":"Hattenhauer","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00041327-199403000-00011","article-title":"Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California","volume":"14","author":"Johnson","year":"1994","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00041327-200306000-00012","article-title":"Pathogenesis of nonarteritic anterior ischemic optic neuropathy","volume":"23","author":"Arnold","year":"2003","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib8","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0161-6420(87)33263-4","article-title":"Anterior ischemic optic neuropathy. IX. Cup-to-disc ratio and its role in pathogenesis","volume":"94","author":"Beck","year":"1987","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.04.008_bib9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ophtha.2007.05.027","article-title":"Nonarteritic anterior ischemic optic neuropathy: Natural history of visual outcome","volume":"115","author":"Hayreh","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.04.008_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00041327-199503000-00002","article-title":"Pain in anterior ischemic optic neuropathy","volume":"15","author":"Swartz","year":"1995","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12886-024-03354-4","article-title":"Visual outcome of various dose of glucocorticoids treatment in nonarteritic anterior ischemic optic neuropathy- a retrospective analysis","volume":"24","author":"Zhao","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/WNO.0000000000000715","article-title":"Risk factors for fellow eye involvement in nonarteritic anterior ischemic optic neuropathy","volume":"39","author":"Chang","year":"2019","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib13","article-title":"Risk factors for non-arteritic anterior ischemic optic neuropathy: a large scale meta-analysis","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ophtha.2026.04.008_bib14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/bjophthalmol-2018-312910","article-title":"Obstructive sleep apnoea and increased risk of non-arteritic anterior ischaemic optic neuropathy","volume":"103","author":"Yang","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib15","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0002-9394(14)72557-7","article-title":"Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy","volume":"118","author":"Hayreh","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001111","article-title":"Metabolic syndrome and its components are associated with non-arteritic anterior ischaemic optic neuropathy","author":"Kohli","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.urology.2017.02.044","article-title":"Prospective case-crossover study investigating the possible association between nonarteritic anterior ischemic optic neuropathy and phosphodiesterase type 5 inhibitor exposure","volume":"105","author":"Flahavan","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.ophtha.2026.04.008_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/WNO.0000000000000615","article-title":"Case of bilateral sequential nonarteritic ischemic optic neuropathy after rechallenge with sildenafil","volume":"38","author":"Neufeld","year":"2018","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ophtha.2010.03.063","article-title":"Interferon alfa-associated anterior ischemic optic neuropathy","volume":"118","author":"Fraunfelder","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.04.008_bib20","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.ophtha.2015.08.022","article-title":"Amiodarone-associated optic neuropathy: a nationwide study","volume":"122","author":"Cheng","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.04.008_bib21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib22","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/jamaophthalmol.2025.1823","article-title":"Association of semaglutide and NAION reviewed","volume":"143","author":"Klonoff","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib23","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamaophthalmol.2025.2489","article-title":"Ocular adverse events with semaglutide: a systematic review and meta-analysis","volume":"143","author":"Natividade","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2025.2493","article-title":"Semaglutide and the eyes-a literature glut, but little clarity","author":"Li","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib25","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: a meta-analysis of randomised controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2026.04.008_bib26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ophtha.2025.12.022","article-title":"Rate and risk of non-arteritic anterior ischaemic optic neuropathy with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis","volume":"26","author":"Liu","year":"2026","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.04.008_bib27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"143","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1001\/jamaophthalmol.2025.1829","article-title":"Association of semaglutide and NAION reviewed","volume":"143","author":"Lum","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib29","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/jamaophthalmol.2025.0349","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy risk among patients with diabetes","volume":"143","author":"Hsu","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26327","article-title":"Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes","volume":"8","author":"Wang","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ophtha.2026.04.008_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy","volume":"274","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26321","article-title":"GLP-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes","volume":"8","author":"Ramsey","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ophtha.2026.04.008_bib33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.04.008_bib34","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.ophtha.2025.03.011","article-title":"Re: Chou et al.: Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study","volume":"132","author":"Lum","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.04.008_bib35","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jamaophthalmol.2025.3720","article-title":"Neovascular age-related macular degeneration and GLP-1 RAs","volume":"143","author":"Alkabbani","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib36","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish-Norwegian cohort study","volume":"27","author":"Simonsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2026.04.008_bib37","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.ophtha.2026.04.008_bib38","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/jamaophthalmol.2025.2332","article-title":"GLP-1RA exposure and nonarteritic anterior ischemic optic neuropathy prevalence by diabetes status","volume":"143","author":"Nagdeve","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib39","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1177\/19322968241268050","article-title":"Real-world evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"18","author":"Klonoff","year":"2024","journal-title":"J Diabetes Sci Technol"},{"issue":"2","key":"10.1016\/j.ophtha.2026.04.008_bib40","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/dom.70200","article-title":"GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: a population-based study","volume":"28","author":"Tesfaye","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2026.04.008_bib41","article-title":"Semaglutide decreases risk of non-arteritic anterior ischemic optic neuroapthy in type 2 diabetic patients","author":"Lieberman","year":"2025","journal-title":"Mil Med"},{"key":"10.1016\/j.ophtha.2026.04.008_bib42","article-title":"Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence","author":"Chen","year":"2025","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.ophtha.2026.04.008_bib43","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.orcp.2025.01.011","article-title":"Semaglutide: Nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system - a disproportionality analysis","volume":"19","author":"Azab","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.ophtha.2026.04.008_bib45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.orcp.2025.03.001","article-title":"Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: an emerging pharmacovigilance signal?","volume":"19","author":"Procacci","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.ophtha.2026.04.008_bib46","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12886-025-04096-7","article-title":"Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting","volume":"25","author":"Zhao","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib47","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/jamaophthalmol.2024.4527","article-title":"Considerations regarding association of semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"142","author":"Maro","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib48","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.26336","article-title":"Incretin receptor agonists and nonarteritic anterior ischemic optic neuropathy and other ocular complications","volume":"8","author":"Ong","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ophtha.2026.04.008_bib49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2026.04.008_bib50","unstructured":"American Academy of Ophthalmology and North American Neuro-Ophthalmology Society issue advice on weight loss drug and eye health. American Academy of Ophthalmology. Accessed October 8, 2025. https:\/\/www.aao.org\/newsroom\/news-releases\/detail\/weight-loss-drug-and-eye-health."},{"key":"10.1016\/j.ophtha.2026.04.008_bib51","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.ophtha.2026.04.008_bib52","article-title":"Prescribing trends of glucagon-like peptide 1 receptor agonists for type 2 diabetes or obesity","volume":"8","author":"Li","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ophtha.2026.04.008_bib53","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1111\/dom.13339","article-title":"Glucagon-like peptide-1 receptor expression in the human eye","volume":"20","author":"Hebsgaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2026.04.008_bib54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.ophtha.2026.04.008_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108271","article-title":"GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension","volume":"33","author":"Sterling","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.ophtha.2026.04.008_bib56","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ophtha.2026.04.008_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","article-title":"Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study","volume":"265","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib58","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamaophthalmol.2024.2514","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"142","author":"Mollan","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib59","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.ophtha.2006.11.035","article-title":"Incipient nonarteritic anterior ischemic optic neuropathy","volume":"114","author":"Hayreh","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.04.008_bib60","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ophtha.2010.03.006","article-title":"Bilateral diabetic papillopathy and metabolic control","volume":"117","author":"Ostri","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.04.008_bib61","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0161-6420(03)00804-2","article-title":"The morphology of an infarct in nonarteritic anterior ischemic optic neuropathy","volume":"110","author":"Tesser","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.04.008_bib62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaophthalmol.2024.6058","article-title":"Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide","volume":"143","author":"Katz","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.04.008_bib63","unstructured":"PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. European Medicines Agency. Accessed October 8, 2025. https:\/\/www.ema.europa.eu\/en\/news\/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy."},{"key":"10.1016\/j.ophtha.2026.04.008_bib64","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1111\/dom.70160","article-title":"Addressing the risk of ocular complications of GLP-1RAs; a multi-disciplinary expert consensus","volume":"27","author":"Carter","year":"2025","journal-title":"Diabetes Obes Metab"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026002460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026002460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:38:03Z","timestamp":1784536683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642026002460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0161642026002460"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.04.008","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}